ACM derived from OGJ patients with early-stage tumours and late-stage tumours increased the frequency of central memory CD4+ T cells compared with untreated cells (untrx: 7.35 ± 0.5 vs. early-stage: 11.39 ± 1.0, p = 0.07 late-stage: 10.66 ± 1.0%, p = 0.02) (Fig. 1B). The gene discussed is CD4; the disease is neoplasm.